Sweden's iZafe Q2 net sales jump despite production delays; maintains forecast

iZafe AB

31/08/2026 07:10

Overview
Sweden life science firm's Q2 net sales more than doubled yr/yr but growth lagged plans
Operating loss widened in Q2, reflecting higher costs and Dutch operations consolidation
Company secured new Swedish contracts, a European patent, and ISO/IEC 27001 certification

Outlook
iZafe Group maintains forecast of 22.5 MSEK in ARR at end-2026, requiring accelerated installations
Company focus for H2 2026 is converting agreements and opportunities into more recurring revenues and improved cash flow
Company adapting production planning to address component lead times and support future growth

Result Drivers
PRODUCTION DELAYS - Co said limited availability of Dosell units and longer customer processes postponed planned installations, slowing revenue growth
HIGHER COSTS - Operating loss widened due to increased costs from Dutch operations consolidation, organizational reinforcements and expanded sales and marketing activities
SCALING-UP INVESTMENTS - Co invested in production and commercial capacity ahead of expected revenue growth, but revenues have not yet caught up with scaling-up efforts

Company press release: ID:nMFN7Zgq64

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 2.64 mln
 
Q2 Adjusted Loss Per Share
 
SEK 0.02
 
Q2 Operating Profit
 
-SEK 7.51 mln
 

Reuters Recommended Reads
Aug 28 - Sweden's Xintela Q2 loss narrows as income rises, costs drop
Aug 28 - Sweden's Elicera Therapeutics Q2 loss widens
Aug 28 - Swedish economy posts strong growth, consumers more upbeat ahead of election

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)